A single dose of fluoxetine reduces neural limbic responses to anger in depressed adolescents.
Liliana P CapitãoRobert ChapmanSusannah E MurphyChristopher-James HarveyAnthony JamesPhilip J CowenCatherine J HarmerPublished in: Translational psychiatry (2019)
Depression in adolescence is frequently characterised by symptoms of irritability. Fluoxetine is the antidepressant with the most favourable benefit:risk ratio profile to treat adolescent depression, but the neural mechanisms underlying antidepressant drugs in the young brain are still poorly understood. Previous studies have characterised the neural effects of long-term fluoxetine treatment in depressed adolescents, but these are limited by concurrent mood changes and a lack of placebo control. There is also recent evidence suggesting that fluoxetine reduces the processing of anger in young healthy volunteers, which is consistent with its effect for the treatment of irritability in this age group, but this remains to be investigated in depressed adolescents. Here we assessed the effects of a single, first dose of 10 mg fluoxetine vs. placebo on neural response to anger cues using fMRI in a sample of adolescents with Major Depressive Disorder (MDD) who had been recently prescribed fluoxetine. As predicted, adolescents receiving fluoxetine showed reduced activity in response to angry facial expressions in the amygdala-hippocampal region relative to placebo. Activity in the dorsal anterior cingulate cortex (dACC) was also increased. No changes in symptoms were observed. These results demonstrate, for the first time in depressed adolescents, that fluoxetine has immediate neural effects on core components of the cortico-limbic circuitry prior to clinical changes in mood. The effect on anger is consistent with our previous work and could represent a key mechanism through which fluoxetine may act to alleviate irritability symptoms in adolescent depression.
Keyphrases
- young adults
- major depressive disorder
- sleep quality
- bipolar disorder
- physical activity
- functional connectivity
- depressive symptoms
- resting state
- mental health
- childhood cancer
- clinical trial
- spinal cord
- phase iii
- middle aged
- multiple sclerosis
- radiation therapy
- spinal cord injury
- squamous cell carcinoma
- high speed
- locally advanced
- open label